These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20670978)

  • 1. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031.
    Picozzi VJ; Abrams RA; Decker PA; Traverso W; O'Reilly EM; Greeno E; Martin RC; Wilfong LS; Rothenberg ML; Posner MC; Pisters PW;
    Ann Oncol; 2011 Feb; 22(2):348-54. PubMed ID: 20670978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759].
    Knaebel HP; Märten A; Schmidt J; Hoffmann K; Seiler C; Lindel K; Schmitz-Winnenthal H; Fritz S; Herrmann T; Goldschmidt H; Krempien R; Mansmann U; Debus J; Diehl V; Büchler MW
    BMC Cancer; 2005 Apr; 5():37. PubMed ID: 15826316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma.
    Schmidt J; Abel U; Debus J; Harig S; Hoffmann K; Herrmann T; Bartsch D; Klein J; Mansmann U; Jäger D; Capussotti L; Kunz R; Büchler MW
    J Clin Oncol; 2012 Nov; 30(33):4077-83. PubMed ID: 23008325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
    Picozzi VJ; Kozarek RA; Traverso LW
    Am J Surg; 2003 May; 185(5):476-80. PubMed ID: 12727570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized multicentre phase II trial comparing adjuvant therapy in patients with interferon alpha-2b and 5-FU alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding event-free survival - CapRI-2.
    Märten A; Schmidt J; Ose J; Harig S; Abel U; Münter MW; Jäger D; Friess H; Mayerle J; Adler G; Seufferlein T; Gress T; Schmid R; Büchler MW
    BMC Cancer; 2009 May; 9():160. PubMed ID: 19470159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial.
    Katz MH; Wolff R; Crane CH; Varadhachary G; Javle M; Lin E; Evans DB; Lee JE; Fleming JB; Pisters PW
    Ann Surg Oncol; 2011 Dec; 18(13):3615-22. PubMed ID: 21701927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.
    Nukui Y; Picozzi VJ; Traverso LW
    Am J Surg; 2000 May; 179(5):367-71. PubMed ID: 10930481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I-II study of 5-fluorouracil, recombinant interferon alpha2a, and cisplatin in combination with external beam radiation therapy followed by surgery in patients with locally advanced carcinoma of the esophagus.
    Damle S; Beitler JJ; Haynes H; Camacho M; Wolf E; Wadler S
    Am J Clin Oncol; 1999 Aug; 22(4):391-5. PubMed ID: 10440197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant intraarterial cisplatin, intravenous 5-flourouracil, and split-course radiation therapy for locally advanced unresectable pancreatic adenocarcinoma: a phase II study of the Puget Sound Oncology Consortium (PSOC-703).
    Thomas CR; Weiden PL; Traverso LW; Thompson T
    Am J Clin Oncol; 1997 Apr; 20(2):161-5. PubMed ID: 9124192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study.
    Linehan DC; Tan MC; Strasberg SM; Drebin JA; Hawkins WG; Picus J; Myerson RJ; Malyapa RS; Hull M; Trinkaus K; Tan BR
    Ann Surg; 2008 Aug; 248(2):145-51. PubMed ID: 18650621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study.
    Al-Sukhun S; Zalupski MM; Ben-Josef E; Vaitkevicius VK; Philip PA; Soulen R; Weaver D; Adsay V; Heilbrun LK; Levin K; Forman JD; Shields AF
    Am J Clin Oncol; 2003 Dec; 26(6):543-9. PubMed ID: 14663369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with alpha-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial.
    Wagener DJ; Wils JA; Kok TC; Planting A; Couvreur ML; Baron B
    Eur J Cancer; 2002 Mar; 38(5):648-53. PubMed ID: 11916546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of advanced pancreatic adenocarcinoma with 5-FU, leucovorin, interferon-alpha-2b, and cisplatin.
    Sporn JR; Buzaid AC; Slater D; Cohen N; Greenberg BR
    Am J Clin Oncol; 1997 Feb; 20(1):81-3. PubMed ID: 9020295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
    Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP
    Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.
    Chakravarthy A; Abrams RA; Yeo CJ; Korman LT; Donehower RC; Hruban RH; Zahurek ML; Grochow LB; O'Reilly S; Hurwitz H; Jaffee EM; Lillemoe KD; Cameron JL
    Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1089-96. PubMed ID: 11072167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group.
    Schrijvers D; Johnson J; Jiminez U; Gore M; Kosmidis P; Szpirglas H; Robbins K; Oliveira J; Lewensohn R; Schüller J; Riviere A; Arvay C; Langecker P; Jacob H; Cvitkovic E; Vokes E
    J Clin Oncol; 1998 Mar; 16(3):1054-9. PubMed ID: 9508190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer.
    Magnin V; Moutardier V; Giovannini MH; Lelong B; Giovannini M; Viret F; Monges G; Bardou VJ; Alzieu C; Delpero JR
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1300-4. PubMed ID: 12654441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of chronomodulated infusional 5-fluorouracil chemoradiation for pancreatic cancer.
    Penberthy DR; Rich TA; Shelton CH; Adams R; Minasi JS; Jones RS
    Ann Oncol; 2001 May; 12(5):681-4. PubMed ID: 11432628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO.
    Kollmannsberger C; Budach W; Stahl M; Schleucher N; Hehr T; Wilke H; Schleicher J; Vanhoefer U; Jehle EC; Oechsle K; Trarbach T; Boehlke I; Kanz L; Hartmann JT; Bokemeyer C
    Ann Oncol; 2005 Aug; 16(8):1326-33. PubMed ID: 15919686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of etoposide, leucovorin, 5-FU, and interferon alpha 2b (ELFI) + G-CSF for patients with pancreatic adenocarcinoma: a Southwest Oncology Group study (SWOG 9413).
    Macdonald JS; Jacobson JL; Modiano M; Moore DF; Gandara DR; Schroder LE; Chapman RA
    Invest New Drugs; 2000 Aug; 18(3):269-73. PubMed ID: 10958597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.